Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Alendronate Clear all
Completed Phase 1 Interventional

Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose

NCT00577850
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
risedronate, alendronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Gainesville, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Results available

A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.

NCT00503113
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
ibandronate [Bonviva/Boniva], Alendronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
60 Years and older · Female only
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Riverside, California • Lakewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Sep 11, 2026, 4:15 PM EDT
Completed No phase listed Observational

Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis

NCT00601068
View directory record Official record
Conditions
Osteonecrosis
Interventions
Observational
Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 11, 2026, 4:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use

NCT01875458
View directory record Official record
Conditions
Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture, Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ), Healthy Volunteers
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults

NCT02057263
View directory record Official record
Conditions
Hepatitis B
Interventions
Alendronate, Hepatitis B Vaccine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 4 Interventional

OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

NCT00130403
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
risedronate sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 11, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

NCT00019695
View directory record Official record
Conditions
Stage IV Prostate Cancer, Bone Metastases, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
alendronate sodium, ketoconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Timeline
1999 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Sep 11, 2026, 4:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss

NCT00221312
View directory record Official record
Conditions
Perimenopausal Bone Loss
Interventions
Fosamax
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 54 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 7, 2008 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Parathyroid Hormone (PTH) With Alendronate for Osteoporosis

NCT00005006
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid Hormone, Alendronate, Teriparatide
Drug
Lead sponsor
Helen Hayes Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2006
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Alendronate and/or Parathyroid Hormone for Osteoporosis

NCT00000400
View directory record Official record
Conditions
Osteoporosis
Interventions
Human parathyroid hormone [hPTH-(1-34)], alendronate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 85 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2013 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 4 Interventional

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

NCT00079924
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
teriparatide, aldrenodate, raloxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 24, 2007 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Alendronate Sodium Tablets (10 mg) and Fosamax Tablets (10 mg)

NCT00983996
View directory record Official record
Conditions
Healthy
Interventions
Alendronate Sodium Tablets, 10 mg, Fosamax Tablets, 10 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 23, 2009 · Synced Sep 11, 2026, 4:15 PM EDT
Active, not recruiting Phase 4 Interventional

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover

NCT05151484
View directory record Official record
Conditions
Age-Related Osteoporosis
Interventions
Teriparatide, Alendronate
Drug
Lead sponsor
Madhumathi Rao
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 11, 2026, 4:15 PM EDT
Terminated Not applicable Interventional Results available

Pilot Study of Fosamax in Spinal Cord Injury

NCT01131884
View directory record Official record
Conditions
Spinal Cord Injury, Osteoporosis
Interventions
Fosamax, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 11, 2026, 4:15 PM EDT
Recruiting Phase 4 Interventional

Bone, Exercise, Alendronate, and Caloric Restriction

NCT05764733
View directory record Official record
Conditions
Bone Loss
Interventions
Bisphosphonate, Resistance Training/Bone-Loading Exercise, Placebo
Drug · Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Treatment of Childhood Osteoporosis With Alendronate (Fosamax)

NCT00001720
View directory record Official record
Conditions
Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study

NCT02139007
View directory record Official record
Conditions
Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
65 Years to 100 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 4 Interventional

EVA: Evista Alendronate Comparison

NCT00035971
View directory record Official record
Conditions
Osteoporosis
Interventions
raloxifene HCI and alendronate Na
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
73
States / cities
Anniston, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2006 · Synced Sep 11, 2026, 4:15 PM EDT
Withdrawn Phase 4 Interventional

The Effects of Alendronate After Cure of Primary Hyperparathyroidism

NCT00359385
View directory record Official record
Conditions
Hyperparathyroidism
Interventions
Alendronate 70mg weekly
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2011 · Synced Sep 11, 2026, 4:15 PM EDT
Recruiting Phase 2 Interventional

Small Trial of Alendronate Impact on the Reservoir of HIV

NCT07216794
View directory record Official record
Conditions
HIV
Interventions
Alendronate, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 11, 2026, 4:15 PM EDT
Completed No phase listed Observational Results available

Alendronate in Juvenile Osteoporosis

NCT00920075
View directory record Official record
Conditions
Juvenile Osteoporosis, Low Bone Density, Fractures
Interventions
Alendronate (Fosamax)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
8 Years to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Results available

Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women

NCT00504166
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
alendronate sodium, placebo comparator
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Sep 11, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents

NCT00921557
View directory record Official record
Conditions
HIV Infection
Interventions
Alendronate, Placebo, Calcium carbonate/vitamin D
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
11 Years to 24 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 11, 2026, 4:15 PM EDT
Enrolling by invitation Phase 4 Interventional

Precision Medicine Approach for Osteoporosis - Follow Up Study

NCT06264609
View directory record Official record
Conditions
Osteoporosis
Interventions
Alendronate, Teriparatide
Drug
Lead sponsor
Paul F Netzel
Other
Eligibility
45 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 11, 2026, 4:15 PM EDT